131 related articles for article (PubMed ID: 3740675)
1. Melphalan may be a more potent leukemogen than cyclophosphamide.
Greene MH; Harris EL; Gershenson DM; Malkasian GD; Melton LJ; Dembo AJ; Bennett JM; Moloney WC; Boice JD
Ann Intern Med; 1986 Sep; 105(3):360-7. PubMed ID: 3740675
[TBL] [Abstract][Full Text] [Related]
2. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
Pedersen-Bjergaard J; Ersbøll J; Sørensen HM; Keiding N; Larsen SO; Philip P; Larsen MS; Schultz H; Nissen NI
Ann Intern Med; 1985 Aug; 103(2):195-200. PubMed ID: 4014901
[TBL] [Abstract][Full Text] [Related]
3. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials.
Greene MH; Boice JD; Greer BE; Blessing JA; Dembo AJ
N Engl J Med; 1982 Dec; 307(23):1416-21. PubMed ID: 6752720
[TBL] [Abstract][Full Text] [Related]
4. Risk of leukemia after chemotherapy and radiation treatment for breast cancer.
Curtis RE; Boice JD; Stovall M; Bernstein L; Greenberg RS; Flannery JT; Schwartz AG; Weyer P; Moloney WC; Hoover RN
N Engl J Med; 1992 Jun; 326(26):1745-51. PubMed ID: 1594016
[TBL] [Abstract][Full Text] [Related]
5. Acute leukemia after alkylating-agent therapy of ovarian cancer.
Reimer RR; Hoover R; Fraumeni JF; Young RC
N Engl J Med; 1977 Jul; 297(4):177-81. PubMed ID: 406560
[TBL] [Abstract][Full Text] [Related]
6. Leukemia following chemotherapy for breast cancer.
Curtis RE; Boice JD; Moloney WC; Ries LG; Flannery JT
Cancer Res; 1990 May; 50(9):2741-6. PubMed ID: 2328500
[TBL] [Abstract][Full Text] [Related]
7. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU).
Boice JD; Greene MH; Killen JY; Ellenberg SS; Keehn RJ; McFadden E; Chen TT; Fraumeni JF
N Engl J Med; 1983 Nov; 309(18):1079-84. PubMed ID: 6353233
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
9. Acute leukemia after chemotherapy (melphalan).
Einhorn N
Cancer; 1978 Feb; 41(2):444-7. PubMed ID: 272946
[TBL] [Abstract][Full Text] [Related]
10. Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung.
Pedersen-Bjergaard J; Osterlind K; Hansen M; Philip P; Pedersen AG; Hansen HH
Blood; 1985 Dec; 66(6):1393-7. PubMed ID: 2998512
[TBL] [Abstract][Full Text] [Related]
11. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.
Pedersen-Bjergaard J; Specht L; Larsen SO; Ersbøll J; Struck J; Hansen MM; Hansen HH; Nissen NI
Lancet; 1987 Jul; 2(8550):83-8. PubMed ID: 2885581
[TBL] [Abstract][Full Text] [Related]
12. Preleukemia and leukemia with 12p- and 19q+ chromosome alterations following Alkeran therapy.
Wilmoth D; Feder M; Finan J; Nowell P
Cancer Genet Cytogenet; 1985 Feb; 15(1-2):95-8. PubMed ID: 3967221
[TBL] [Abstract][Full Text] [Related]
13. Leukemia following chemotherapy for ovarian cancer.
Kaldor JM; Day NE; Pettersson F; Clarke EA; Pedersen D; Mehnert W; Bell J; Høst H; Prior P; Karjalainen S
N Engl J Med; 1990 Jan; 322(1):1-6. PubMed ID: 2104664
[TBL] [Abstract][Full Text] [Related]
14. Acute leukaemia after alkylating-agent therapy of ovarian cancer.
Bell DR; Woods RL; Levi JA
Med J Aust; 1982 Sep; 2(5):243-4. PubMed ID: 7132879
[No Abstract] [Full Text] [Related]
15. Risk of leukemia after platinum-based chemotherapy for ovarian cancer.
Travis LB; Holowaty EJ; Bergfeldt K; Lynch CF; Kohler BA; Wiklund T; Curtis RE; Hall P; Andersson M; Pukkala E; Sturgeon J; Stovall M
N Engl J Med; 1999 Feb; 340(5):351-7. PubMed ID: 9929525
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults.
Cuzick J; Erskine S; Edelman D; Galton DA
Br J Cancer; 1987 May; 55(5):523-9. PubMed ID: 3300761
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of secondary acute nonlymphocytic leukemias. Cytological aspects (a review).
Raposa T; Várkonyi J; Gráf F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(2):180-5. PubMed ID: 6208100
[TBL] [Abstract][Full Text] [Related]
18. Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years.
Kulkarni S; Powles R; Treleaven J; Singhal S; Horton C; Sirohi B; Bhagawati N; Tait D; Saso R; Killick S; Pinkerton R; Atra A; Meller S; Mehta J
Bone Marrow Transplant; 2000 Feb; 25(4):365-70. PubMed ID: 10723578
[TBL] [Abstract][Full Text] [Related]
19. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
[TBL] [Abstract][Full Text] [Related]
20. Acute leukemia after melphalan treatment for ovarian carcinoma.
Blythe JC
J Med Assoc State Ala; 1977 Nov; 47(5):42-3, 57. PubMed ID: 925549
[No Abstract] [Full Text] [Related]
[Next] [New Search]
